Category Archives: leishmaniasis

Dr. Jacinto Convit Turns 100: A Birthday More-Than-Worthy of Celebration

 

By Dr. Mirta Roses Periago

Jacinto_ConvitOne of the most influential medical experts in leprosy and leishmaniasis celebrated his 100th birthday last week on September 11 – an impressive feat in and of itself. Dr. Jacinto Convit’s work on some of the world’s most challenging public health concerns led to the development of an anti-leprosy vaccine and an immunotherapy for leishmaniasis – not to mention a Nobel Prize nomination and countless awards for his work.

Dr. Convit’s focus on leprosy began in the 1930’s while working in a leper colony in his home country of Venezuela. At the time, leprosy was highly feared as an incurable and highly contagious disease. But in 1940, Dr. Convit gave leprosy patients hope by using blocked Mycobacterium leprae to treat more than 14,000 people. Building on this success, Dr. Convit developed a vaccine for treating and preventing leprosy.

This vaccine led to a multidrug treatment which reduced Venezuela’s leprosy rate to a point that the disease was no longer a public health concern. However, Dr. Convit continues to stress the need for more research and development to fully eradicate the disease.

Dr. Convit’s knowledge of parasitic diseases has also lead to influential work on leishmaniasis — a disfiguring neglected tropical disease (NTD) transmitted by sand flies. He has worked to break down the stigma associated with both leprosy and leishmaniasis – diseases that cause victims to be shunned by their own communities.

Dr. Convit’s dedication to improving millions of lives through global health is truly an inspiration. As he has previously stated, “The only limitation to work is imagination.” Learn more about Dr. Jactino Convit in a video interview that is part of the Pan American Health Organization (PAHO) Reflections project to honor the voices of public health specialists from different fields who have made contributions to health in the Americas.

Dr. Mirta Roses is an NTD Special Envoy for the Global Network and former Director of the Pan American Health Association (PAHO).

2013 G20 Summit: Das Vi Danya to NTDs?

 

9677929867_2d903fe0da_z

The 2013 G20 Summit concluded in St. Petersburg last week amid debates on how to respond to the Syrian civil war and recent chemical attacks in the country. What world leaders did not discuss though was another crisis that is happening in Syria and around the developing world at large: an epidemic of cutaneous leishmaniasis and other NTDs.

Leishmaniasis (also known as Aleppo Evil) is an NTD that is spread by the bite of infected sandflies. At best, the disease produces disfiguring lesions on the face and body, which take more than a year to heal and often lead to shame, stigma and social isolation. Leishmaniasis has plagued Syria and other parts of the Middle East, North Africa and Central Asia for hundreds of years, but efforts to develop an effective vaccine for it, led by the Sabin Vaccine Institute, are relatively new.

Prior to the civil war, leishmaniasis posed a moderate public health threat to Syrians, but its transmission and pathology were tapered through surveillance and the availability of sanitation, insecticidal spraying, beds nets and anti-parasitic therapies. However, as Dr. Peter Hotez recounted in his testimony on NTDs before the House Foreign Affairs’ Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations last June, the conflict and subsequent break down of public health has lead to a resurgence of the disease. While reports cannot be verified, it is estimated that there are more than 100,000 new cases of leishmaniasis across the country and in the growing refugee camps outside Syria.

Beyond Syria and leishmaniasis specifically, NTDs are a slew of 17 diseases that directly impact 1.4 billion people around the world. They not only cause malnutrition, pain, deformity and blindness, but can also prevent people from working or going to school and exacerbate poverty and inequality. NTDs pose a significant threat to the goals of the G20 to promote food security, financial inclusion, and human resource development, as outlined in the St. Petersburg Development Outlook.

“In order to reach these goals, we must address issues that undercut the G20’s efforts to boost sustainable, inclusive growth,” said Amb. Michael Marine, CEO of the Sabin Vaccine Institute. “The G20’s efforts to improve nutrition and help build a skilled workforce will fall short if we do not the tackle other barriers that prevent people from working productively.”

The Global Network welcomes the G20’s emphasis on economic growth as central to boosting prosperity among the world’s poor and its support for the post-2015 development agenda, but human development must be emphasized as a driver of long-term economic growth and poverty reduction.

We hope the G20 will continue to strive to give people across the globe a chance to reach their full economic and social potential, especially by recognizing the impact of NTDs on economic growth and prosperity at the G20 Development Working Group meeting this October in DC. The Global Network will also be watching for NTDs at next year’s summit in Australia, and you can bet that we will be following up. , here we come!

Northeastern University Launches Integrated Global Health Initiative to Tackle NTDs

By Angela Herring

Drug discovery is by definition slow and costly. The multiphase process, which begins with basic science research and ends with clinical trials, can consume up to two decades and more than a billion dollars.

Credit: Mary Knox Merrill, Northeastern University

For NTDs such as African sleeping sickness and Chagas disease, the outlook is even grimmer: anti-infective drugs tend to have higher fail rates than other drugs, as parasites quickly develop resistance. And since NTDs predominantly affect low-income populations, the incentive for big pharmaceutical companies to improve on current treatments is low.

But current treatments are ghastly. In some cases, the drugs themselves can be poisonous and have high mortality rates. With one-third of the planet’s population at risk for NTDs, a new paradigm is required.

Northeastern University chemistry and chemical biology professor Michael Pollastri believes an open-source science model will hasten the drug discovery process. Despite great advances in NTD research over the last decade, the global research effort is largely uncoordinated. Continue reading

A short history of leishmania vaccines

By: Charles Ebikeme

In February of this year we saw the launch of the first human trial for a new vaccine for visceral leishmaniasis (leishmaniasis is one of the neglected tropical diseases, and it has been blogged about it in the past here on End the Neglect).

Photo credit: CDC

The new trial was launched by the InfectiousDiseaseResearchInstitute (IDRI) in Seattle, Washington with the plan to hold a further Phase 1 trial in India. The Bill & Melinda Gates Foundation is funding the Phase 1 clinical trials, as part of the recently announced worldwide partnership with the WHO and 13 pharmaceutical companies to control or eliminate 10 neglected tropical diseases.

This new vaccine development can be added to a fast-expanding list of so-called “anti–poverty” vaccines; such as the famed RTS,S malariavaccine that last year proved to be effective (albeit not to levels some would deem completely effective), and vaccines in development for rabies, hookworm, schistosomiasis and dengue. Continue reading